Products Pipeline

The XTLbio pipeline is generated by systematically identifying, validating and in-licensing therapeutic candidates with advantages over current therapies and which address unmet medical needs. Today 3 compounds are actively being developed, all in clinical stages.

XTLbio Pipeline

  Preclinical Phase I Phase II Phase III  
hCDR1
         
Erythropoietin (EPO)